Vlastos AT - Search Results

1

Effect of 4-hydroxyphenylretinamide on human cervical epithelial and cancer cell lines.

Zou C, Vlastos AT, Yang Li, Wang J, Brewer M, Follen M. Zou C, et al. Among authors: vlastos at. J Soc Gynecol Investig. 2003 Jan;10(1):41-8. J Soc Gynecol Investig. 2003. PMID: 12517593

2

Effects of difluoromethylornithine on growth inhibition and apoptosis in human cervical epithelial and cancerous cell lines.

Zou C, Vlastos AT, Yang L, Wang J, Nishioka K, Follen M. Zou C, et al. Among authors: vlastos at. Gynecol Oncol. 2002 May;85(2):266-73. doi: 10.1006/gyno.2002.6599. Gynecol Oncol. 2002. PMID: 11972386

3

Biomarkers and their use in cervical cancer chemoprevention.

Vlastos AT, Schottenfeld D, Follen M. Vlastos AT, et al. Crit Rev Oncol Hematol. 2003 Jun;46(3):261-73. doi: 10.1016/s1040-8428(02)00107-5. Crit Rev Oncol Hematol. 2003. PMID: 12791426 Review.

4

Why phase II trials in cervical chemoprevention are negative: what have we learned?

Follen M, Vlastos AT, Meyskens FL Jr, Atkinson EN, Schottenfeld D. Follen M, et al. Among authors: vlastos at. Cancer Causes Control. 2002 Nov;13(9):855-73. doi: 10.1023/a:1020660527600. Cancer Causes Control. 2002. PMID: 12462551 Free article.

5

Quantitative histopathology and chromosome 9 polysomy in a clinical trial of 4-HPR.

Yamal JM, Cox D, Hittelman WN, Boiko I, Malpica A, Guillaud M, MacAulay C, Follen M, Vlastos AT. Yamal JM, et al. Among authors: vlastos at. Gynecol Oncol. 2004 Aug;94(2):296-306. doi: 10.1016/j.ygyno.2004.04.030. Gynecol Oncol. 2004. PMID: 15297165 Clinical Trial.

6

Cervical chromosome 9 polysomy: validation and use as a surrogate endpoint biomarker in a 4-HPR chemoprevention trial.

Kim HG, Yamal JM, Xu XC, Hu W, Boiko I, Linares A, Vlastos AT, Atkinson EN, Malpica A, Hittelman WN, Follen M. Kim HG, et al. Among authors: vlastos at. Gynecol Oncol. 2005 Dec;99(3 Suppl 1):S32-7. doi: 10.1016/j.ygyno.2005.07.039. Epub 2005 Sep 9. Gynecol Oncol. 2005. PMID: 16154183

7

Lymphangioma circumscriptum of the vulva: a review of the literature.

Vlastos AT, Malpica A, Follen M. Vlastos AT, et al. Obstet Gynecol. 2003 May;101(5 Pt 1):946-54. doi: 10.1016/s0029-7844(03)00048-6. Obstet Gynecol. 2003. PMID: 12738156 Review.

8

Results of a phase II double-blinded randomized clinical trial of difluoromethylornithine for cervical intraepithelial neoplasia grades 2 to 3.

Vlastos AT, West LA, Atkinson EN, Boiko I, Malpica A, Hong WK, Follen M. Vlastos AT, et al. Clin Cancer Res. 2005 Jan 1;11(1):390-6. Clin Cancer Res. 2005. PMID: 15671570 Clinical Trial.

9

Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients.

Saldivar JS, Lu KH, Liang D, Gu J, Huang M, Vlastos AT, Follen M, Wu X. Saldivar JS, et al. Among authors: vlastos at. Gynecol Oncol. 2007 Oct;107(1 Suppl 1):S223-9. doi: 10.1016/j.ygyno.2007.07.024. Epub 2007 Sep 6. Gynecol Oncol. 2007. PMID: 17825393

10

Loop electrosurgical excision procedure in vulvar intraepithelial neoplasia treatment.

Vlastos AT, Levy LB, Malpica A, Follen M. Vlastos AT, et al. J Low Genit Tract Dis. 2002 Oct;6(4):232-8. doi: 10.1097/00128360-200210000-00008. J Low Genit Tract Dis. 2002. PMID: 17051029

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

27 results

Search Page

Filters